PVI
AMLX icon

Pura Vida Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Pura Vida Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-68,652
Closed -$1.93M – 197
2022
Q3 		$1.93M Buy
68,652
+58,102
+551% +$1.45M 0.11% 134
2022
Q2 		$203K Buy
10,550
+550
+6% +$6.53K 0.01% 189
2022
Q1 		$129K Buy
+10,000
New +$226K ﹤0.01% 217

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pura Vida Investments's AMLX Position: Q4 2022 in Review

Pura Vida Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2022, closing a stake of 68,652 shares — an estimated $1.93M sold.

Pura Vida Investments first reported a position in AMLX in Q1 2022 and held it in 3 quarters. The position peaked at $1.93M in Q3 2022. 133 funds tracked by Wall St. Rank hold AMLX as of Q4 2022.

  • Pura Vida Investments reported no remaining Amylyx Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 68,652 Amylyx Pharmaceuticals shares in Q4 2022, an estimated $1.93M.
  • Pura Vida Investments first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Pura Vida Investments's Amylyx Pharmaceuticals position peaked at $1.93M in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.